Independent Circadian and Sleep/Wake Regulation of Adipokines and Glucose in Humans

Steven A. Shea, Michael F. Hilton, Christine Orlova, R. Timothy Ayers, and Christos S. Mantzoros

Medical Chronobiology Program (S.A.S., M.F.H., R.T.A.), Brigham and Women's Hospital, Boston, Massachusetts 02115; Harvard Medical School (S.A.S., M.F.H., C.S.M.), Boston, Massachusetts 02115; Division of Endocrinology, Diabetes, and Metabolism (C.O., C.S.M.), Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215

Leptin and adiponectin play important physiological roles in regulating appetite, food intake, and energy balance and have pathophysiological roles in obesity and anorexia nervosa. To assess the relative contributions of day/night patterns in behaviors (sleep/wake cycle and food intake) and of the endogenous circadian pacemaker on observed day/night patterns of adipokines, in six healthy subjects we measured circulating leptin, soluble leptin receptor, adiponectin, glucose, and insulin levels throughout a constant routine protocol (38 h of wakefulness with constant posture, temperature, and dim light, as well as identical snacks every 2 h) and throughout sleep and fasting periods before and after the constant routine. There were significant endogenous circadian rhythms in leptin, glucose, and insulin, with peaks around the usual time of awakening. Sleep/fasting resulted in additional systematic decreases in leptin, glucose, and insulin, whereas wakefulness/food intake resulted in a systematic increase in leptin.

Thus, the day/night pattern in leptin is likely caused by combined effects from the endogenous circadian pacemaker and day/night patterns in behaviors. Our data imply that alterations in the sleep/wake schedule would lead to an increased daily range in circulating leptin, with lowest leptin upon awakening, which, by influencing food intake and energy balance, could be implicated in the increased prevalence of obesity in the shift work population.

(From J Clin Endocrinol Metab 90: 2537–2544, 2005)

Leptin and adiponectin are adipocyte secreted hormones that regulate energy balance and metabolism, play important roles in the pathogenesis of obesity and the metabolic syndrome (1–4), and contribute to adverse cardiovascular consequences (5–7). There are day/night patterns in plasma leptin and adiponectin concentrations, with leptin rising (8–12) and adiponectin falling during the night (13). Considering the potential pathophysiological roles of these adipocytokines in the epidemic of obesity and associated disorders, it is important to fully understand the factors that control their day/night patterns of release. For instance, nocturnal eating syndrome and shift work are often associated with obesity and the metabolic syndrome (14–20). Although the mechanisms underlying these associations remain unknown, it is possible that disturbances in day/night adipokine patterns, induced by alterations in the sleep/wake and eating schedule, as occurs with jet lag and shift work, could, in turn, influence appetite, food intake, and energy balance in these populations and could have important implications for the increased obesity, diabetes, and cardiovascular disease in the shift work population (21–23). However, no prior studies have fully elucidated the causes underlying the day/night patterns of adipocytokine concentrations, and no study has directly assessed the relative contributions to this pattern from the endogenous body clock [the circadian pacemaker located in the suprachiasmatic nuclei of the hypothalamus (24)] and day/night patterns in behaviors (such as the sleep/wake cycle and food intake).

Thus, the aim of the current experiment was to test the hypothesis that endogenous circadian factors influence circulating adipokine concentrations and glucose in humans. A secondary aim was to determine the magnitude of any such circadian effect in relation to independent behavioral effects induced by day/night patterns in behaviors (the sleep/wake cycle and food intake). To overcome many of the limitations of previous studies, we made measurements throughout a protocol that permitted separation of endogenous circadian effects from systematic influences related to sleep or fasting and wakefulness or food intake by studying subjects: first, during sleep and fasting; second, throughout maintained wakefulness for 38 h with constant posture, constant temperature, and constant dim light, with identical snacks every 2 h; and third, throughout a period of sleep and fasting after this constant routine protocol (25). We used samples drawn every hour to measure concentrations of leptin, soluble leptin receptor (sOB-R) [representing the main leptin binding activity in serum, which indirectly determines the amount of biologically active free leptin at the hypothalamus (26–27)], adiponectin, glucose, and insulin in hourly blood samples taken throughout the entire protocol.

Subjects and Methods

We studied six adult male subjects, whose mean age was 30.7 yr (range, 22–46) and whose mean body mass index (BMI) was 25.2 kg.m\(^{-2}\) (range, 23.0–26.6). Subjects were healthy, with no significant medical disorders, as assessed by history, physical examination, overnight polysomnography, psychological examination, pulmonary function tests, a 12-lead ECG, and routine blood and urine chemistry. The study was

First Published Online February 1, 2005

Abbreviations: BMI, Body mass index; CBTmin, core body temperature minimum; CV, coefficient of variation; sOB-R, soluble leptin receptor.

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.

2537
approved by the local Human Subjects internal review board. Subjects provided written informed consent before participation.

Protocol

To ensure a stable circadian baseline before entry into the laboratory, subjects were asked to establish a regular sleep-wake schedule, with their habitual bedtimes and wake times varying by no more than 1 h each day for at least 2 wk before the laboratory study. This schedule was verified by time-logged telephone calls of bedtimes and wake times for 2 wk as well as activity monitoring for 3–7 d (wrist-worn Actigraph; Ambulatory Monitoring, Ardsley, NY). For 1 wk before the study and throughout the study, subjects abstained from caffeinated drinks, smoking, and any medication. Each subject was then studied in an individual laboratory room isolated from external time cues. As part of a separate aim assessing circadian cardiopulmonary rhythmicity, noninvasive cardiopulmonary measurements were made every 2–4 h, including for 2–9 d before the current study, which enabled further laboratory acclimatization and a relatively steady state. To assess endogenous circadian effects, we used a 38-h constant routine protocol involving constant wakefulness, posture (semirecumbent), temperature (23 ± 2 °C), and dim light (4–5 lux), with identical meals every 2 h as previously described (25). Subjects were also monitored during sleep before the constant routine, and during a period of recovery sleep immediately after the constant routine (each sleep opportunity was 10 h). The constant routine protocol is designed to unmask underlying circadian rhythms as it reduces or eliminates other physiological influences from the environment, varied behaviors, large meals, and sleep. Upon awakening on the morning of the constant routine, subjects remained in bed and awake in a semirecumbent position for 38 h. Only minor postural changes and no vigorous activities were permitted. Experimenters were present in the laboratory throughout the constant routine to ensure that the subjects remained awake. A bottle was used to collect urine, and a bedpan was used for any bowel movements. A normal diet, consisting of three meals and snacks, large meals, and sleep. Upon awakening on the morning of the constant routine, subjects remained in bed and awake in a semirecumbent position for 38 h. Only minor postural changes and no vigorous activities were permitted. Experimenters were present in the laboratory throughout the constant routine to ensure that the subjects remained awake. A bottle was used to collect urine, and a bedpan was used for any bowel movements. A normal diet, consisting of three meals plus a snack, was provided on the day before the constant routine; however, to avoid the effects of large meals on adipocyte physiology during the constant routine, small identical snacks were given every 2 h. The overall calories per 24 h, including during baseline, were calculated for each subject using the Harris-Benedict formula with an activity factor of 1.3. Each meal or snack was comprised of 25% fat, 50% carbohydrate, and 25% protein. The subjects also received up to 3.5 liters of fluids every 24 h period.

Measurements

Recordings of two electroencephalography channels, two electrooculography channels, and a submental electromyogram (Vitatap recorder; TEMEC, Kerkrade, The Netherlands) were made to enable scoring of sleep stages in the baseline and recovery sleep periods. Core body temperature was recorded throughout using a rectal temperature sensor (Yellow Springs Instrument Co., Inc., Yellow Springs, OH) to provide a marker of the endogenous circadian pacemaker.

Blood was sampled hourly during both wakefulness and sleep via an indwelling 18-gauge catheter in a forearm vein, and samples were taken from an adjacent room via a 12-foot small lumen extension catheter. Catheter patency was maintained between samples by infusing 0.45% saline with 10,000 IU/liter heparin at a rate of 20 ml/h. Blood samples were transferred to vacutainer tubes, centrifuged at 4 °C, and the resulting plasma was stored in polystyrene tubes at −20 °C until the assays were performed. Plasma adiponectin levels were measured using a RIA from Diagnostics Systems Laboratory (DSL, Webster, TX) with a sensitivity of 2 ng/ml and intraassay coefficient of variation (CV) of 6.6%. Plasma leptin levels were measured using a RIA (DSL) with a sensitivity of 0.5 ng/ml and intraassay CV of 8.3%. Plasma CRP-4 levels were measured using a commercially available ELISA (DSL) with a sensitivity of 0.8 ng/ml and intraassay CV between 5.5 and 6.6%. Plasma insulin was assayed using a commercially available paramagnetic-particle chemiluminescent immunoassay (Beckman Access B; Diamond Diagnostics, Holliston, MA) with a sensitivity of 0.03 μU/ml and an average intraassay CV of 3.1–5.6%. Plasma glucose was assayed using a commercially available assay (ACE glucose reagent; Alfa Wassermann, West Caldwell, NJ) with a sensitivity of 1 mg/dl and an average intraassay CV less than 2%.

Analysis of circadian rhythm and behavioral influences on glucose and hormones

All temperature, hormonal, and glucose data collected in the first 5 h of the constant routine were excluded from analysis to avoid the effects of altered posture and sleep-wake transition. Each subject’s phase and period of the core body temperature circadian rhythm were estimated by nonlinear least-squares regression (28). Using the estimated core body temperature minimum (CBTmin) as an arbitrary phase marker (0 degrees), all data were then assigned a specific circadian phase from 0–359 degrees depending upon the time lag between the collected data and CBTmin as well as the duration of each individual’s estimated circadian period. The average circadian period for the subjects in this study was 24.6 h (SEM = 0.2 h).

For the individuals’ data, the circadian phases and amplitudes of the hormonal and glucose variables were estimated by cosinor analysis (29). This technique uses multiple linear regression to calculate the mesor (the average level around which other fluctuations occur), the amplitude and phase of any circadian rhythm (relative to CBTmin), and any underlying linear trend (e.g. due to the effects of prolonged wakefulness or meals). The cosinor analysis also incorporates a circadian harmonic term (−12 h cosine), which provides better data fitting of rhythms that are not precisely cosinor in shape (because the summation of circadian plus harmonic cosine waveforms with different amplitudes and phases permits an infinite number of shapes). A graphical example of the cosinor analysis is shown in Fig. 1.

The focus of this study is on the average changes within individuals over time rather than differences between individuals. To calculate the group mean circadian rhythmicity of the hormonal and glucose data independent from behavioral factors, it was necessary to subtract each individual’s linear trend and to express the data in normalized units (i.e. the percentage difference from the mean). Then, individuals’ data were aligned with respect to their subject-specific CBTmin, and cosinor analysis was performed to estimate the circadian amplitude and phase (relative to CBTmin). This group analysis excluded a linear trend term (this had already been subtracted from each subject’s data).

To calculate the group mean behavioral influences on the hormonal and glucose data (i.e. the effects of prolonged wakefulness or meals) independent from circadian rhythmicity, it was necessary to subtract each individual’s estimated circadian rhythm from the data and to express the data as the percentage difference from the mean. Then individuals’ data were aligned with respect to the sleep/wake schedule (instead of the circadian phase), and linear regression was performed to

![Graph](https://example.com/graph.png)
estimate the rate of change throughout prolonged wakefulness. Separate analogous linear regression analyses were performed to estimate the independent effects of sleep/fasting on the hormones and glucose after subtracting the circadian components. Because circadian rhythmicity was calculated during the constant routine, this last analysis relied upon our assumption that the circadian component could be extrapolated from the constant routine data to the sleep periods on either side of the constant routine.

Results

Circadian effects (independent from behavioral effects)

The cosinor analyses of leptin accounted for between 88 and 95% of the variability in individuals' data (i.e., \( r^2 \) for the cosinor analyses ranged from 0.88–0.95). Four of the six subjects had a significant circadian rhythm in circulating leptin \( (P < 0.05) \). The peak-to-trough amplitudes of the fundamental circadian rhythms averaged 1.4 ng/ml, equivalent to a daily fluctuation of 21% around the leptin mesor of 6.5 ng/ml. For the group, the circadian variation in circulating leptin was highly significant \( (P < 0.0001) \), with a peak-to-trough value, over the 24 h, of 16% of the mesor. The average circadian waveform is shown in Fig. 2 (upper left). Although all of these measurements were made during continued wakefulness, it can be seen that the endogenous circadian system caused a steady increase in leptin across the time that corresponds to the habitual sleep period in this group of subjects (with a peak just after the usual time of awakening, and a trough in the afternoon). Thus, the independent circadian profile is considerably different (i.e., \( \sim 8 \) h phase delayed) from the regular day/night leptin profiles when behaviors and meals are uncontrolled (see Discussion).

There was much less variability within subjects in the concentration of sOB-R. None of the subjects had a significant

![Fig. 2. Group mean circadian variations in circulating leptin, glucose and insulin and lack of detectable circadian variations in sOB-R and adiponectin. Circadian phases are double plotted for better visualization of any rhythmicity. The ordinates are all the same scale and expressed as percentage deviation from the respective mean after subtraction of any linear trends in the individuals' data. The mean and SE values of the data are shown segregated into 60° bins (\( \sim 4 \) h). The solid lines describe the cosinor models. Significant circadian rhythms are indicated by \( P \) values where applicable. Although these data were collected during wakefulness, the group average habitual sleep period when living outside the laboratory is depicted by a double-headed arrow on each plot. There were significant circadian rhythms in circulating leptin, glucose, and insulin (left panels). The circadian system caused a steady increase in leptin across the usual sleep period and increases in both insulin and glucose around the time of habitual awakening. In contrast, there was no detectable circadian rhythm in either circulating sOB-R or adiponectin levels (right panels).](https://academic.oup.com/jcem/article-abstract/90/5/2537/2836423)
There was a very small, but significant, decline in group mean adiponectin during wakefulness equivalent to 0.18 \( \mu g/ml \) over the usual period of 16 h of continuous wakefulness (i.e. 4% decrease around the adiponectin mesor of 4.05 \( \mu g/ml \)). However, this is presumably of little physiological consequence because only one of the six subjects had a significant linear decline in adiponectin across the constant routine. Similarly, there were no statistically significant changes in group mean glucose or insulin attributable to prolonged wakefulness/meals.

**Effect of sleep/fasting (independent from circadian effects)**

In contrast to the increased circulating leptin during wakefulness, each subject had a significant decrease in leptin across each sleep period (when subjects were also fasting), both before the constant routine and during recovery sleep. The mean decrease was \(-0.6 \, ng/ml\) per hour of sleep/fasting (range, \(-0.34\) to \(-1.10 \, ng/ml\) per hour). This is equivalent to \(-4.8 \, ng/ml\) over the usual period of 8 h of sleep, representing an independent sleep/fasting-related fluctuation of 74% around the leptin mesor of 6.5 ng/ml (Fig. 3). Notably, the rate of fall during sleep/fasting was much greater than the rate of increase during wakefulness/eating (mean, +0.21 ng/ml per hour, see above).

The rate of fall of circulating leptin during sleep/fasting was almost identical in the baseline period and during recovery sleep (Fig. 3), despite improvements in average sleep efficiency (5.5\% absolute increase; \( P < 0.01 \), paired \( t \) test), decreased sleep onset latency (13 min; not significant), and an average increase in nonrapid-eye-movement sleep stages III and IV (6.1\% absolute increase; \( P < 0.05 \)). The similar rate of decline despite altered sleep suggests that fasting rather than sleep per se causes the linear decrease in circulating leptin.

There were no independent sleep-related changes in sOB-R or adiponectin, but there were independent sleep-related decreases in both glucose and insulin. The mean reduction in circulating insulin attributable to sleep/fasting was \(-0.45 \, \mu IU/ml\) per hour, equivalent to \(-3.6 \, \mu IU/ml\) over the usual sleep period of 8 h (representing an independent
sleep/fasting-related reduction in insulin of 36% around the mesor of 10.1 μU/ml). The mean reduction in circulating glucose was −0.65 mg/dl per hour, equivalent to −5.2 mg/dl over the usual sleep period of 8 h (reduction in glucose of 5% around the mesor of 103.4 mg/dl).

Discussion

Although our prior work has suggested that nocturnal elevations of leptin are probably due to more than a circadian influence, and that sleep per se may also play a role (30), to our knowledge, this study is the first to directly assess the independent influences of the endogenous circadian pacemaker and various physiological behaviors on adipocyte and glucose physiology using a validated circadian protocol. We found significant endogenous circadian rhythms in leptin, glucose, and insulin, with peaks around the usual time of awakening, but no circadian rhythms in sOB-R or adiponectin. In addition, we detected systematic decreases in leptin, glucose, and insulin attributable to the effects of sleep/fasting, and a systematic increase in leptin attributable to wakefulness/food intake. Because adipokines play important physiological and pathophysiological roles in obesity and the metabolic syndrome (31), these findings may provide potentially important implications in situations when physiological behaviors and the circadian system become misaligned, such as with jet lag, shift work, or clinical conditions such as the nocturnal eating syndrome (32–34).

Almost all previous studies quantifying the day/night pattern in adipokine, glucose, or insulin concentrations allowed sleep/fasting to occur at night and wakefulness/food intake during the day, making it impossible to determine whether the changes seen across the day and night could be due to the pattern of food intake over the 24-h period or the endogenous circadian system. Leptin levels have a robust 24-h rhythm (8–12), with leptin increasing monotonically from the morning through the afternoon and evening and peaking in the early part of the nocturnal sleep period. Shifting the time of both sleep and meals by 12 h also shifted the pattern of circulating leptin by the same period (35), but circadian rhythms may have also been changing during the protocol independent from food intake because there was no control of behaviors or light exposure during the wakefulness episodes. Use of continuous enteral administration and shifting of the sleep schedule by 8 h reveals possible independent circadian rhythm and sleep effects on circulating leptin (36). However, there were limitations in this study including an inability to assess the entire circadian cycle effect, the likely altered sleep quality after an acute sleep schedule shift, and the fact that enteral administration of nutrients may alter hormone levels by bypassing any important neural or endocrine signals from the stomach and gut (e.g., ghrelin) (32).

In the current study, we separated the potential circadian and behavioral influences and found that the endogenous circadian profile of circulating leptin is considerably different (i.e., approximately 8 h phase delayed) from that seen in the previously published, not fully controlled studies. Importantly, we found that, after subtracting the circadian effect, sleep/fasting was associated with a monotonic decline in leptin, and wakefulness/eating was associated with a monotonic increase in leptin. Therefore, these data suggest that the previously documented day/night pattern in leptin is caused by the combined effects of the endogenous circadian pacemaker and the day/night patterns in behaviors, with the latter having the greater effect across the 24-h cycle.

There is growing evidence of an endogenous circadian rhythm controlling circulating glucose (37). For example, observational studies in humans indicate that there is a day/night pattern in circulating glucose and insulin, with highest levels in the morning (38). Similar to leptin, studies on the effect of sleep on insulin and glucose regulation in healthy subjects (33) suggest the existence of independent circadian and sleep/fasting-related influences on glucose regulation. In a circadian study similar to the current study, but with constant glucose infusion, it was found that the first part of the sleep period was associated with a sharp increase in circulating glucose (due to a decrease in glucose tolerance that almost entirely counteracts any fasting-related drop in glucose), followed by a slight decline in the second half of an 8-h sleep period and fasting. When sleeping during the daytime, there is also an immediate increase in circulating glucose followed by a reduction over time (33–34, 39). Our data extend the observations from these relatively uncontrolled or observational studies by assessing these effects independently through subtracting the endogenous circadian components and examining the residual relationships between behaviors and circulating glucose and insulin. We found that sleep/fasting causes significant systematic reductions in both glucose and insulin, which is consistent with data from the second half of the sleep periods in these earlier studies. We show that healthy humans do have an endogenous circadian rhythm of glucose and insulin, with a peak at the usual time of awakening, at a time similar to that of the circadian-related peak in leptin (Fig. 2). Thus, there appears to be a circadian correlation between insulin and leptin (at least for the times of peak insulin and leptin) (Fig. 2), consistent with the previously detected correlation in longer studies of chronic diurnal fasting (40). Whether the associations found herein are due to a synchronous pacemaker effect or due to the physiologic feedback loop reciprocally regulating insulin and leptin levels remains to be demonstrated by intervention studies.

Results in our overweight, but nonobese, subjects in the current study (average BMI, 25 kg/m²) indicated a lack of a significant circadian rhythm of adiponectin. We recently reported that circulating adiponectin concentrations in healthy lean men (average BMI, 22.8 kg/m²) exhibited a day/night variation, with a significant decline at night, reaching a minimum in the early morning (13). In contrast, a similar study in obese subjects (average BMI, 57.5 kg/m²) failed to demonstrate a similar day/night variation, suggesting that important differences exist between lean vs. obese subjects (41). These differences among studies suggest that the day/night pattern in adiponectin (13) in lean individuals is mainly attributable to day/night patterns in behaviors (sleep/fasting and wakefulness/meals) rather than the endogenous circadian cycle and that this effect can be observed in obese individuals.

Shift work and travel to different time zones are increas-
ingly prevalent in our society. There is also abundant evidence that shift work leads to obesity (15–20) and associated comorbidities, including insulin-resistance, the metabolic syndrome, and adverse cardiovascular events (21–23). The causes of shift-work-related obesity remain unknown, but increased calorie intake and/or decreased energy expenditure are important contributors (42). Based on the data presented herein, we hypothesize that changes of the day/night pattern of circulating leptin could be implicated in the pathogenesis of shift-work-related obesity. More specifically, summing the three factors that influence circulating leptin tested in the current study (i.e. the circadian system, wakefulness/meals, and sleep/fasting), we have estimated how the usual day/night pattern of circulating leptin is likely to be altered by adjustments in the sleep/wake schedule (Fig. 4). With sleep occurring at the usual phase of the circadian rhythm (left panel of Fig. 4), circadian and behavioral fluctuations are almost out of phase and cancel each other to a large extent: leptin reaches a peak during the usual sleep period, declines throughout the rest of the night, begins to increase throughout the morning, reaches a plateau for approximately 8 h during the daytime, and then rises again in the 3 h before the usual sleep time. This profile is similar to published 24-h leptin profiles in protocols that permit sleep at night. In contrast, the daily leptin profile is likely to change quite considerably when altering the sleep/wake schedule relative to the circadian timing. When sleep occurs at an unusual phase of the circadian rhythm (i.e. shifted by 12 h) as may occur during shift work, the circadian and behavioral fluctuations of leptin would likely be in phase (Fig. 4). This would result in a fluctuation in circulating leptin of more than double the normal 24-h fluctuation. Moreover, in this model, the person would awaken with a very low level of leptin, which would be expected to increase appetite and alter neuroendocrine function at this time (4, 43). Note, these profiles are based on our data in which identical sized snacks are taken equispaced throughout the waking period. Such profiles may change if subjects have three or four larger meals during wakefulness. Thus, whether or not this simulated model reflects exactly the biology of night shift work in the real world remains to be examined by performing experiments in subjects working on a night shift schedule.

Although common obesity is associated with hyperleptinemia in humans (44–46), subjects with leptin receptor mutation(s), as well as hypoleptinemic subjects with either congenital or acquired leptin deficiency, are also obese (47–48). Moreover, it has been suggested that even heterozygotes for mutations of the leptin gene (approximately 10% of the population) also become obese due to relative leptin deficiency (47–48). We have recently shown that either short-term induced hypoleptinemia due to fasting, or long-term hypoleptinemia in conditions in which caloric expenditure exceeds caloric intake, is associated with dysregulation of the central mechanisms regulating neuroendocrine function and energy homeostasis (4, 43). In addition, leptin administration is also effective in regulating insulin resistance in hypoleptinemic states, including both congenital leptin deficiency and acquired states of leptin deficiency (1, 31, 49). Similar to other hormones with pulsatile and day/night patterns of secretion, these observations raise the possibility that the lower daily nadir in circulating leptin/free leptin levels (27, 41) may be of relevance to metabolism, neuroendocrine function, and development of obesity in the shiftwork population; but this remains to be directly shown by interventional studies.

Limitations of the study include the fact that our separation of circadian and behavioral effects relies upon the assumption that these effects are additive, as suggested by the

![24 h leptin profile with sleep at usual circadian phase](image1)

**Fig. 4.** Adjusting sleep/wake schedule relative to the endogenous circadian phase increases the magnitude of the 24-h leptin profile. **Left panel,** Group mean 24-h circulating leptin profile with sleep occurring at the usual phase of the circadian rhythm; **right panel,** the same data but with sleep occurring at an unusual phase of the circadian rhythm (i.e. shifted by 12 h) as may occur during shift work. The sleep periods are shown by gray shaded blocks. The abscissa represents time of day. In each panel the thin dashed line depicts the group mean linear decrease during sleep/fasting and the linear increase during wakefulness/food intake, and the dotted line depicts the group mean circadian rhythmicity. The circadian time is the same in each panel, with the peak leptin attributable to the circadian system occurring around 0900 h (~3 h after the CBTmin). The top line in each panel represents circulating leptin (mesor plus circadian plus behavioral effects). When sleep occurs at an unusual phase of the body clock (right panel), the circadian and behavioral fluctuations are in phase, and the resultant circulating leptin has a larger 24-h fluctuation.
statistical analyses. This needs to be directly studied by future experiments such as a forced desynchrony study where the circadian and behavior rhythms are experimentally uncoupled (50). We were also unable to assess independent effects of meals from sleep, or independent effects of fasting from sleep, but overwhelming evidence from this study and other studies suggests that fasting and meals have greater effects when compared with sleep and wakefulness effects. Our findings are quite different from other recent research showing that experimentally restricted sleep (4 h per night for 6 nights) lowered both glucose tolerance (51) and the 24-h profile of leptin (52), raising the possibility that incremental sleep restriction may have different effects from acute sleep deprivation. Thus, further experiments, possibly of longer duration, are needed to sort this out.

In summary, we found significant endogenous circadian rhythms in leptin, glucose, and insulin, with peaks around the usual time of waking, but no circadian rhythms in sOB-R or adiponectin. In addition, we detected systematic decreases in leptin, glucose, and insulin attributable to the effects of sleep/fasting, and a systematic increase in leptin attributable to wakefulness/food intake. Our data imply that alterations in the sleep/wake schedule can lead to an increased peak-to-trough daily swing in the physiologically active circulating free leptin, which may influence food intake and energy balance and could thus be implicated in the increased obesity and cardiovascular disease in the shift work population (15). Further studies are needed to assess whether the 24-h leptin profile in response to three meals/d would be different; but, because the circadian peak in leptin coincides with the usual time of awakening in the absence of shift work (left panel of Fig. 4), altering the sleep schedule in either direction and by any amount is expected to always cause a lower trough level of leptin and hypoleptinemia upon awakening. The important clinical relevance of these fluctuations and the need for further interventional studies in the shift work population is further supported by similar observations in patients with nocturnal eating disorders who have an attenuated nocturnal rise in plasma leptin when compared with weight matched controls, suggesting that their nocturnal eating could be a result of the absence of a nocturnal anorexigene signal provided by leptin (14).

Acknowledgments

This work was supported by National Heart, Lung, and Blood Institute Grants R01 HL64815 and K24 HL74446 (to S.A.S.), General Clinical Research Center Grant MO1 RR02635 (to Brigham and Women’s Hospital), and National Institute of Diabetes and Digestive and Kidney Diseases Grant ROI 57875 (to C.S.M.).

Received November 12, 2004. Accepted January 21, 2005.

Address all correspondence and requests for reprints to: Steven A. Shea, Ph.D., Medical Chronobiology Program, Brigham and Women’s Hospital, Sleep Disorders Research Program at Beth Israel Deaconess Medical Center, 75 Francis Street, Boston, Massachusetts 02215. E-mail: sshea@hms.harvard.edu or Christos S. Mantzoros, M.D., Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Stoneman 816, Boston, Massachusetts 02215. E-mail: cmantzor@bidmc.harvard.edu.

References

1. Coleman RA, Herrmann TS 1999 Nutritional regulation of leptin in humans. Diabetologia 42:539–544.
2. Cupples WA 2003 Peptides that regulate food intake. Am J Physiol Regul Integr Comp Physiol 284:R1370–R1374.
3. Rosenbaum M, Leibel RL 1999 The role of leptin in human physiology. N Engl J Med 341:913–915.
4. Welt CK, Chan J 2004 Recombinant human leptin administration in women with hypothalamic amenorrhea. N Engl J Med 351:987–997.
5. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama K, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Arakawa Y, Oikawa S, Horie M, Noda M, Yokoyama T, Minokoshi Y, Takahashi M, Yamashita M, Kishida K, Nishizawa H, Matsuda M, Yamauchi T, Matsuoka Y 2002 Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737.
6. Matsuzawa Y, Funahashi T, Nakamura T 1999 Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adiponectin-derived active substances. Ann NY Acad Sci 892:146–154.
7. Ukkola O, Santaniemi M 2002 Adiponectin: a link between excess adiposity and associated comorbidities? Mol Med 8:696–702.
8. Havel PJ, Townsend R, Chaump L, Teff K 1999 High-fat meals reduce 24-h circulating leptin concentrations in women. Diabetes 48:334–341.
9. Heptulla R, Smithen A, Teague B, Tamborlane WV, Mz Y, Caprio S 2001 Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J Clin Endocrinol Metab 86:1496–1497.
10. Licinio J, Negrao AB, Mantzoros C, Kaklamani V, Wong ML, Bongiorno PB, Negro PP, Mullia A, Veldhuis JD, Cearnal L, Flier JS, Gold PW 1998 Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab 83:1212–1217.
11. Saad MF, Riad-Gabriel MG, Khan A, Sharma A, Michael R, Jinaoguda SD, Boyadjian R, Steil GM 1998 Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 83:453–459.
12. Sinha MK, Ohanesian JP, Heiman ML, Krulitchius A, Stephens TW, Magosin S, Marco C, Caro JF 1996 Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Invest 97:1344–1347.
13. Gaviria A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS 2003 Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 88:2838–2843.
14. Birketvedt GS, Florholmen J, Sundsfjord J, Osterud B, Dinges D, Bilker W, Stunkard A 1999 Behavioral and neuroendocrine characteristics of the night-eating syndrome. JAMA 282:657–663.
15. Ishizaki M, Morikawa Y, Nakagawa H, Honda R, Kawakami N, Haratani T, Kobayashi F, Araki S, Yamada Y 2004 The influence of work characteristics on body mass index and waist to hip ratio in Japanese employees. Ind Health 42:41–49.
16. Di Lorenzo L, D’Epoglia G, Zocchetti C, L’Abbate N, Basso A, Pannaccilli N, Cignarelli M, Giorgino R, Soleo L 2003 Effect of shift work on body mass index: results of a study performed in 319 glucose-tolerant men working in a Southern Italian industry. Int J Obes Relat Metab Disord 27:1353–1358.
17. Lowden A, Holmbak U, Akerstedt T, Forslund A, Forslund J, Lennernas M 2001 Time of day type of food–relation to mood and hunger during 24 hours of constant conditions. J Hum Ergol (Tokyo) 30:381–386.
18. Karlsson BH, Knutsson AB, Wahren J, Ingelsson E 2003 Metabolic disturbances in male workers with rotating three-shift work. Results of the WOLF study. Int Arch Occup Environ Health 76:424–430.
19. Parkes KR 2002 Shift work and age as interactive predictors of body mass index among offshore workers. Scand J Work Environ Health 28:64–71.
20. Karlsson B, Knutsson A, Lindahl B 2001 Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med 58:747–752.
21. Knutsson A 1989 Shift work and coronary heart disease. Scand J Soc Med Suppl 44:1–36.
22. Nakamura K, Shimai S, Kikuchi S, Tominaga K, Takahashi H, Tanaka M, Nakano S, Motohashi Y, Nakadaia H, Yamamoto M 1997 Shift work and risk factors for coronary heart disease in Japanese blue-collar workers: serum lipids and anthropometric characteristics. Occup Med (Lond) 47:142–146.
23. Schein AJ 1999 Clinical study of the month. Does chronic sleep deprivation predispose to metabolic syndrome? Rev Med Liege 54:898–900.
24. Schleidt WJ 2002 Suprachiasmatic nucleus. Curr Biol 12:R644.
25. Cesler IA, Allan JS, Strogatz SH, Ronda JM, Sanchez R, Rios CD, Freitag WD, Richardson GS, Kronauer RE 1986 Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 233:667–671.
26. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS 2003 Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88:4823–4831.
27. Chan JL, Bluhser S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS 2002 Regulation of circulating soluble leptin receptor levels by gender, adi-
posity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51:2105–2112

28. Brown EN, Czeisler CA 1992 The statistical analysis of circadian phase and amplitude in constant-routine core-temperature data. J Biol Rhythms 7:177–202

29. Nelson W, Tong YL, Lee JK, Halberg F 1979 Methods for cosinor-rhythmometry. Chronobiologia 6:305–323

30. Mullington JM, Chan JL, Van Dongen HP, Szuba MP, Samaras J, Price NJ, Meier-Ewert HK, Dinges DF, Mantzoros CS 2003 Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol 15:851–854

31. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL 1992 Circadian and ultradian variations of leptin in normal man under continuous enteral nutrition: relationship to sleep and body temperature. J Clin Endocrinol Metab 83:1893–1899

32. La Fleur SE 2003 Daily rhythms in glucose metabolism: suprachiasmatic nucleus output to peripheral tissue. J Neuroendocrinol 15:315–322

33. Bolli GB, De Feo P, De Cosimo S, Perriello G, Ventura MM, Calcinaro F, Bolli C, Campbell B, Brunetti P, Gerich JE 1984 Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 33:1150–1153

34. Van Cauter E, Blackman JD, Roland D, Spire JP, Reifeloff S, Polonsky KS 1991 Modulation of glucose regulation and insulin secretion by circadian rhythm and sleep. J Clin Invest 86:554–562

35. Polonsky KS, O’Rahilly S 1991 Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884

36. Dijk DJ, Duffy JF, Czeisler CA 1992 Circadian and sleep/wake dependent aspects of subjective alertness and cognitive performance. J Sleep Res 1:112–117

37. Spiegel K, Leproult R, Van Cauter E 1999 Impact of sleep debt on metabolic and endocrine function. Lancet 354:1343–1349

38. Spiegel K, Leproult R, Van Cauter E 2003 Impact of sleep debt on physiological rhythms. Rev Neurol (Paris) 159:6511–6520

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.